Maximum Amount of Royalty Reduction. In no event shall the amounts payable to AstraZeneca under Section 4.4 be reduced by operation of Section 4.4.3 by more than [***] ([***]) of what would otherwise be due by operation of Section 4.4. No unused reduction may be carried over into any subsequent Calendar Year. For clarity, to the extent the adjustments in Section 4.4 or this 4.4.4 cover periods in which payments are due based on more than one royalty rate described in Section 4.4.1, the Net Sales to which such adjustments apply shall be distributed on a pro rata basis among the applicable royalty rates set forth in Section 4.4.1.
Maximum Amount of Royalty Reduction. In no event shall the royalties payable to Nanomerics under Section 7.9 be reduced by more than [**] in any Calendar Quarter as a result of the reductions set forth in this Section 7.10.
Maximum Amount of Royalty Reduction. In no event shall the royalty rate payable to Rigel under Section 8.5(a) or (b) in respect of any particular country be reduced by more than [ * ] percent ([ * ]%) in any Calendar Quarter as a result of the reductions set forth in Sections 8.5(c), (d), (e) or (f). [ * ].
Maximum Amount of Royalty Reduction. In no event shall the amounts payable to AstraZeneca under Section 4.4 be reduced by operation of Section 4.4.4 to a royalty rate less than [***].
Maximum Amount of Royalty Reduction. Notwithstanding any term or condition of this Agreement to the contrary, in no event shall the amounts payable to MedImmune under Section 4.5.1 on a global basis with respect to any Calendar Quarter be less than the amount equal to [***] percent [***] of the amounts that would be payable pursuant to Section 4.5.1 if such amounts due were calculated (a) without regard to any reductions that may be permitted pursuant to Section 4.5.3 and (b) without limitation to clause (a), in the case of any Combination Product, without regard to any adjustment for Combination Product that may otherwise be permitted pursuant to the definition of Net Sales.
Maximum Amount of Royalty Reduction. Notwithstanding any term or condition of this Agreement to the contrary, in no event shall the royalties payable to AstraZeneca pursuant to Sections 7.2.1 and 7.2.2 be reduced by more than [***] in any Calendar Quarter as a result of any reductions, offsets or setoffs permitted pursuant to this Agreement, whether taken in a Calendar Quarter alone or in the aggregate with other permitted reductions or offsets, including pursuant to Section 7.2.3 and Section 8.15. Reductions not applied or exhausted in any Calendar Quarter as a result of this Section 7.2.4 may be carried into future Calendar Quarters until fully applied or exhausted, subject to the foregoing sentence, and [***] and with respect to which a reduction in royalties is available pursuant to Section 7.2.3, may be carried into [***] or subsequent Calendar Quarters, as the case may be, until fully used in accordance with this Section 7.2.4.
Maximum Amount of Royalty Reduction. In no event shall the royalty rate payable to Lexicon under this Section 7.3 be reduced below [**] of the royalty rates set forth in Section 7.3.1 in any Calendar Year as a result of the reductions set forth in Sections 7.3.3(ii) and 7.3.3(iv), collectively.
Maximum Amount of Royalty Reduction. In no event shall the royalty rate payable to Licensor under this Section 5.3 in respect of any country or Licensed Product be reduced by more than [***] percent ([***]%) of what it would otherwise be by operation of Section 5.3.3 or 5.3.5. Credits not exhausted in any [***] may be carried into future [***], subject to the foregoing sentence.
Maximum Amount of Royalty Reduction. In no event shall the royalty payable to Rigel under Section 8.4(a) (Non-CNS Penetrant Products) or 8.4(b) (CNS Penetrant Products), as applicable, with respect to a given Product in a given country be reduced by more than [*] in aggregate in any Calendar Quarter as a result of the reductions set forth in [*].
Maximum Amount of Royalty Reduction. In no event shall the amounts payable to MedImmune under this Section 5.3 be reduced [***]. For the avoidance of doubt such royalty reductions payable to MedImmune set forth in Section 5.3(vi) do not apply to any royalties due and payable by MedImmune under the Humabs Agreement. Licensee shall remain responsible for such royalties as set forth in the Humabs Agreement (whether subject to reduction or not) in accordance with Section 5.3(iii).
